Europe Autoimmune Disease Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Desk Research

Desk research was used to set the fact base for demand, testing patterns, and pricing logic across Europe, then to confirm country coverage before modeling. We reviewed public sources such as Eurostat health statistics, the European Commission and ECDC health publications, and OECD health data. We also used guidance documents published by European clinical and laboratory medicine bodies (for example on ANA testing and related algorithms) to align how autoimmune test pathways are expected to run.

For technique and utilization signals, we also checked peer reviewed journal articles for testing pathways, positivity rates, and shifts from IFA to ELISA or multiplex methods. To keep the model grounded in commercial reality, we reviewed company annual reports, investor presentations, association websites, and reputable medical press that discuss assay launches and lab automation trends. For cross checks on company revenue footprints and patent activity, we selectively used paid subscriptions that provide company financial intelligence and patent database access, since they help validate whether a firm is present in the category by country. The desk research sources cited here are illustrative only, and additional public references were used for data collection, validation, and clarification.

Primary Interviews and Surveys

Primary work was done through expert interviews and structured surveys with diagnostic laboratories, hospital lab teams, distributors, and clinical stakeholders who influence test selection and volume. To reduce country bias, we spread discussions across major European markets and the rest of Europe, then used the inputs to confirm test mix, average selling price ranges, and how quickly newer multiplex platforms are being adopted. When a datapoint looked inconsistent with the desk research signals, we returned to respondents to retest assumptions before finalizing the model.

Distribution of primary research fieldwork respondents

Sizing starts with a top-down build where we reconstruct the diagnostic demand pool by country using healthcare activity signals and autoimmune disease testing intensity, then allocate it across major techniques used in routine practice. The totals are corroborated with selective bottom-up approximations, such as sampling assay volumes and price bands by technique, and cross checking supplier exposure and channel feedback, which are used to adjust the country totals when gaps appear.

Key inputs that shaped the model included the mix of systemic versus localized autoimmune testing, the share of ANA and related autoantibody panels within overall autoimmune workups, technique mix shifts between immunofluorescence assays, ELISA, western blotting, multiplex immunoassay, and agglutination, and the split of testing between hospitals and independent clinical laboratories. We also tracked practical pricing markers, including reagent kit ASP ranges by technique, instrument placement intensity in larger labs, and the effect of reimbursement and procurement cycles on adoption timing.

For forecasting, scenario analysis was used, since changes in guideline driven testing pathways and lab automation adoption can create step changes rather than smooth curves. Assumptions for growth by country and technique were kept consistent with what primary experts described for utilization, procurement timelines, and the speed at which labs standardize new panels. When bottom-up checks were thin in smaller countries, we used proxy ratios from comparable markets and then validated them with regional distributors and lab stakeholders.

Validation was handled through triangulation across three layers, model outputs, independent market signals, and expert feedback, so one weak data point did not drive the final number. Variance checks were run at country and technique levels, and outliers were reviewed again against the assumed test mix and price ladders before sign-off. If a mismatch persisted, we re-contacted respondents to confirm whether it was driven by procurement timing, reimbursement effects, or a one-time event.

Every report is refreshed annually, and interim updates are done when a material event changes demand or pricing (for example, a major guideline change or a large procurement shift). Before delivery, an analyst performs a final pass to incorporate the latest public signals and interview feedback, so clients receive an updated view rather than an older snapshot.

Published market values for autoimmune disease diagnostics in Europe can differ because each study draws the line differently on what counts as autoimmune diagnostics revenue, and because pricing and technique mix are treated differently across models. Differences also show up when one estimate uses an older base year, applies a single Europe level growth rate, or does not recheck country totals against real testing pathways.

The main gap comes from whether routine inflammatory markers and broad panels are fully counted as autoimmune diagnostics, and how quickly newer multiplex testing is assumed to replace older methods, which shifts the weighted ASP over time. Some estimates also model Europe as one block, while our approach keeps country level checks so higher spend markets do not over-influence the rest of the region, and currency timing and inflation assumptions stay consistent across the series.

Benchmark comparison

The table shows that scope decisions explain most of the spread, and the gap is largest when routine testing is counted without confirming the autoimmune diagnostic pathway. The scope filter that limits counting to autoimmune specific testing intent, and the technique level ASP mix that is refreshed using country checks, are the steps that keep Mordor Intelligence tied to a repeatable Europe demand build rather than a broad lab testing total.